Drugs / CT0991
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07233018 | Nov 2025 → Jun 2026 overdue | acute myeloid leukemia | MEI HENG | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06709131 | Jan → Aug 2025 | acute myeloid leukemia | He Huang | Suspended | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT0991 | “This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, efficacy, and cellular pharmacokinetics of CT0991 in patients with relapsed or...” NCT06709131 ↗ |